To be launched in 2025
New Options for Growth Treatment
Low dose, low AE.
Stable structure, high bioactivity
Aimed at reducing dose & pursuing long-termtreatment efficacy and safety
Patented in many countries
Pegpesen, also known as Inpegsomatropin or PEG-GH, is a long-acting growth hormone fusion protein. It consists of recombinant human growth hormone covalently linked to polyethylene glycol via site-specific conjugation. The modification extends serum half-life, enabling weekly dosing. Molecular formula: C191H297N51O59S; CAS No.: 1468630-68-3.
Contraindicated in active malignancy, closed epiphyses, or acute critical illness. Requires storage at 2°C–8°C protected from light. Strict monitoring for intracranial hypertension, glucose intolerance, and injection site reactions is mandatory during clinical use.